4
Changes in Ownership
Atea Pharmaceuticals, Inc. Filed Acc 0001193125-26-036272
Chief Commercial Officer gave up 11,570 shares (to pay taxes)
- Chief Commercial Officer acquired 42,083 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Vavricka John Chief Commercial Officer | 2026-01-31 | Option exercise | +42,083 | 94,164 | D | ||
| Vavricka John Chief Commercial Officer | 2026-01-31 | Shares withheld for taxes | −11,570 | $4.24 | $49,057 | 82,594 | D |
| Derivatives | |||||||
| Vavricka John Chief Commercial Officer | 2026-01-31 | Option exercise · Restricted Stock Units | −33,333 | 0 | D | ||
| Vavricka John Chief Commercial Officer | 2026-01-31 | Option exercise · Restricted Stock Units | −8,750 | 0 | D | ||
| Vavricka John Chief Commercial Officer | 2026-01-31 | Grant or award · Stock Option (Right to Buy) | +119,520 | 119,520 | D | ||
Loading xslF345X05/ownership.xml…